NT201 (Xeomin) in upper limb post-stroke spasticity: results of a double-blind, placebo-controlled, randomised, multi-centre trial

Objective: Efficacy and safety of NT 201 in treatment of patients with upper limb post-stroke spasticity were investigated in a placebo-controlled, multi-centre trial. Background: NT 201 is a new formulation of botulinum neurotoxin type A which is free from complexing proteins. In contrast to other preparations of botulinum neurotoxin, NT 201 has not been associated with immunogenicity in animal models. Methods: Patients with a score of 2 or more points for wrist and finger flexor tone in the Ashworth Scale were included. All patients had to have moderate severity of the principle therapeutic target selected on…